title: Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP.
abstract: BACKGROUND
  The ever-present threat of infectious disease, e.g. influenza pandemics, and the increasing need for new and effective treatments in immunotherapy are the driving forces that motivate research into new and innovative vaccine platforms. Ideally, such platforms should trigger an efficient CTL response, be safe, and easy to manufacture. We recently developed a novel nanoparticle adjuvant comprised of papaya mosaic virus (PapMV) coat protein (CP) assembled around an RNA. The PapMV nanoparticle is an efficient vaccine platform in which the peptide antigen is fused to the C-terminus of the PapMV CP, leading to nanoparticles presenting surface-exposed epitope. The fusion stabilizes the epitope and improves its immunogenicity. We found recently that C-terminal fusions are not always efficient, depending on the nature of the peptide fused to the platform.
  
  
  RESULTS
  We chose a CTL epitope derived from the nucleocapsid (NP) of influenza virus (NP₁₄₇₋₁₅₅) for this proof-of-concept demonstration. Recombinant nanoparticles harbouring a fusion at the N-terminus were more efficient in triggering a CTL response. Efficacy appeared to be linked to the stability of the nanoparticles at 37°C. We also showed that discs--smaller than nanoparticles--made of 20 subunits of PapMV CP are less efficient for induction of a CTL response in mice, revealing that assembly of the recombinant PapMV CP into nanoparticles is crucial to triggering an efficient CTL response.
  
  
  CONCLUSIONS
  The point of fusion on the PapMV vaccine platform is critical to triggering an efficient CTL response. Efficacy is linked to nanoparticle stability; nanoparticles must be stable at 37°C but remain susceptible to cellular proteases to ensure efficient processing of the CTL epitope by cells of the immune system. The results of this study improve our understanding of the PapMV vaccine platform, which will facilitate the design of efficient vaccines to various infectious threats.
authors.affiliation: Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boul. Laurier, Quebec city, PQ G1V 4G2, Canada.
authors.forename: Cindy
authors.initials: C
authors.lastname: Babin
authors.forename: Nathalie
authors.initials: N
authors.lastname: Majeau
authors.forename: Denis
authors.initials: D
authors.lastname: Leclerc
mesh_terms: D000276:Adjuvants, Immunologic; D000595:Amino Acid Sequence; D000818:Animals; D029441:Carica / Q000821:virology; D003001:Cloning, Molecular; D004591:Electrophoresis, Polyacrylamide Gel; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000276:immunology*; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009029:Mosaic Viruses / Q000378:metabolism*; D053758:Nanoparticles / Q000737:chemistry*; D019251:Nucleocapsid / Q000737:chemistry / Q000276:immunology*; D010455:Peptides / Q000276:immunology; D015202:Protein Engineering / Q000379:methods; D011994:Recombinant Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D018984:Epitopes, T-Lymphocyte; D007252:Influenza Vaccines; D010455:Peptides; D011994:Recombinant Proteins
references.citation: Protein Expr Purif. 2011 Jun;77(2):146-52
references.pmid: 21266198
references.citation: Eur J Immunol. 2002 Nov;32(11):3305-14
references.pmid: 12555676
references.citation: J Virol. 2008 Jan;82(2):785-94
references.pmid: 17989184
references.citation: J Mol Biol. 2012 Sep 14;422(2):263-73
references.pmid: 22659319
references.citation: J Biotechnol. 2007 Feb 1;128(2):423-34
references.pmid: 17126944
references.citation: Vaccine. 2012 Mar 28;30(15):2535-42
references.pmid: 22326774
references.citation: Vaccine. 2010 Aug 2;28(34):5617-26
references.pmid: 20600515
references.citation: J Gen Virol. 1989 Sep;70 ( Pt 9):2325-31
references.pmid: 2778435
references.citation: Virology. 2007 Jun 20;363(1):59-68
references.pmid: 17320136
references.citation: Vaccine. 2009 Aug 13;27(37):5069-76
references.pmid: 19563889
references.citation: J Gen Virol. 2006 Oct;87(Pt 10):3103-3112
references.pmid: 16963770
references.citation: Nat Rev Immunol. 2012 Jun 22;12(7):479-91
references.pmid: 22728526
references.citation: Cell. 2010 Mar 19;140(6):805-20
references.pmid: 20303872
references.citation: Annu Rev Med. 2002;53:149-72
references.pmid: 11818468
references.citation: Annu Rev Immunol. 2011;29:185-214
references.pmid: 21219183
references.citation: FEBS J. 2006 Jan;273(1):14-25
references.pmid: 16367744
references.citation: Vaccine. 2008 Jun 25;26(27-28):3395-403
references.pmid: 18511159
references.citation: FEBS J. 2008 Apr;275(7):1474-1484
references.pmid: 18312419
references.citation: Vaccine. 2011 Sep 22;29(41):7154-62
references.pmid: 21651936
references.citation: PLoS One. 2012;7(2):e31925
references.pmid: 22363771
references.citation: J Virol. 2008 Mar;82(6):3147-53
references.pmid: 18184704
references.citation: J Virol. 2007 Feb;81(3):1319-26
references.pmid: 17121795
references.citation: FEBS J. 2012 Jun;279(11):2004-11
references.pmid: 22524169
references.citation: J Immunol. 2008 Sep 15;181(6):4168-76
references.pmid: 18768874
references.citation: Virus Res. 2012 Jun;166(1-2):109-15
references.pmid: 22406128
references.citation: Curr Top Microbiol Immunol. 2014;375:47-59
references.pmid: 22021043
references.citation: Science. 1993 Nov 26;262(5138):1448-51
references.pmid: 8248784